stability testing comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.
Last reviewed on 2026-02-11. Where a claim depends on a specific study, the study is described rather than over-claimed.
Mass spectrometry provides complementary information by measuring molecular mass. Electrospray ionization or matrix-assisted laser desorption/ionization can confirm the expected peptide mass and reveal related impurities with different masses. It does not directly quantify all species because ionization efficiency varies. When coupled to liquid chromatography, LC-MS can assign masses to chromatographic peaks. This helps distinguish target peptide from truncation, oxidation, or deletion products. Mass accuracy and resolution determine how confidently a mass can be matched to a proposed structure.
Other methods address specific purity concerns. Amino acid analysis gives compositional data after hydrolysis, while capillary electrophoresis separates by charge-to-mass ratio. Karl Fischer titration measures residual water, and gas chromatography can detect residual solvents. Nuclear magnetic resonance can identify organic impurities but is less sensitive for trace levels. No single test covers all possible impurities, so purity testing usually combines orthogonal methods and reports the conditions used. The choice of methods is guided by the impurity classes of interest.
Impurity profiling identifies and quantifies substances that coexist with the target peptide. These include deletion sequences, truncated peptides, oxidized variants, and residual protecting groups from synthesis. Reversed-phase chromatography can separate many of these impurities, but co-elution remains a challenge for closely related species. Mass spectrometry helps assign identities to impurity peaks, and impurity limits are often set as area percentages relative to the main peak. Regulatory guidelines for research-grade peptides are less strict than those for therapeutic products, so specifications vary by supplier.
Quality control for peptides involves setting specifications for identity, purity, and counterion content. Batches are tested against these specifications before release. Purity specifications often require a minimum area percentage by high-performance liquid chromatography, such as 95% or 98%, depending on the intended application. Additional tests may include water content, acetate or trifluoroacetate content, and residual solvents. These parameters affect the net peptide content and the accuracy of subsequent laboratory experiments.
Stability testing examines how peptide purity changes over time under defined conditions. Accelerated studies use elevated temperatures and humidity to predict degradation pathways, while long-term studies store samples at recommended temperatures. Common degradation reactions include oxidation of methionine, deamidation of asparagine, and hydrolysis of peptide bonds. The results inform expiration dates and storage recommendations for research materials. Lyophilized peptides are generally more stable than solutions, but both forms can degrade if exposed to moisture, oxygen, or repeated freeze-thaw cycles.
| Property | Value | Notes |
|---|---|---|
| Typical analytical method | RP-HPLC with UV detection | Separates by hydrophobicity; purity is method-dependent |
| Confirmatory method | LC-MS or MALDI-TOF MS | Provides molecular mass and impurity mass information |
| Common detection wavelength | 214 nm or 220 nm | Peptide bond absorbance; also 280 nm for aromatic residues |
| Typical purity specification | 95% or greater by HPLC area | Common research grade; exact threshold depends on application |
| Sample preparation | Dissolve in water/acetonitrile with acid | Formic acid or trifluoroacetic acid often used |
Purity and potency are related but distinct concepts in peptide testing. Purity describes the proportion of the main peptide relative to other detected substances, while potency refers to the biological or functional activity of a defined amount. A highly pure peptide can still have low potency if it is misfolded, aggregated, or chemically modified at a critical residue. Conversely, a less pure preparation may retain high activity if the impurities are inactive. Clear reporting separates these attributes and states the assay used for each.
Peptide purity specifications describe which tests define an acceptable lot and how results are reported. A certificate of analysis commonly lists a reverse-phase HPLC purity value, a mass spectrometry identity result, water content, counterion content, and residual solvent data. The specification may set a minimum area percent, such as 95% or 98%, depending on the intended use and grade. No universal threshold applies to all peptides, because sequence length, hydrophobicity, and manufacturing route influence achievable purity.
Quality control includes system suitability, blank injections, and reference standards. System suitability checks column performance and retention time reproducibility, while blank runs detect carryover or mobile-phase contaminants. Reference standards help calibrate retention time and detector response. Without these controls, a purity value is difficult to compare across laboratories or over time. Documentation of instrument settings and integration parameters is also part of quality control, and acceptance criteria should be set before samples are analyzed.
Impurity profiles can include deletion peptides, oxidized forms, truncated sequences, and residual solvents. Some impurities arise during synthesis, cleavage, or purification, while others form during storage. Purity testing often focuses on peptide-related impurities, whereas residual solvents and counterions require separate assays. The significance of a given impurity depends on its amount and properties, which may not be established for a research peptide. Reporting an impurity profile is more informative than reporting a single purity number.
Peptide purity specifications describe the minimum acceptable result from a defined test. A certificate of analysis may list HPLC purity, mass spectrometry identity, appearance, and counterion content. Specifications are method-dependent, so a value obtained with one gradient or wavelength may differ from another. For research use, common thresholds include 95% and 98% by RP-HPLC, but the appropriate limit depends on the application. The specification should always name the analytical method and acceptance criterion.
=== Available forms === Each Contrave tablet contains 8 mg naltrexone and 90 mg bupropion. Once full dosing is reached (after 4 weeks of administration), the total dosage of Contrave for treating overweight or obesity is two tablets twice daily or 32 mg naltrexone and 360 mg bupropion per day.
== Building a PBPK model == The model equations follow the principles of mass transport, fluid dynamics, and biochemistry in order to simulate the fate of a substance in the body. Compartments are usually defined by grouping organs or tissues with similar blood perfusion rate and lipid content (i.e. organs for which chemicals' concentration vs. time profiles will be similar). Ports of entry (lung, skin, intestinal tract...), ports of exit (kidney, liver...) and target organs for therapeutic effect or toxicity are often left separate. Bone can be excluded from the model if the substance of interest does not distribute to it. Connections between compartment follow physiology (e.g., blood flow in exit of the gut goes to liver, etc.)
. Express each concentration value as the ratio c/c0, where c0 is the concentration in a [hypothetical] standard state, with a numerical value of 1, by definition. Express the concentrations on the mole fraction scale. Since mole fraction has no dimension, the quotient of concentrations will, by definition, be a pure number. The first and second options above give identical numerical values for an equilibrium constant. Furthermore, since a concentration
There's no way it (KFC) could have grown as it did without the Collectramatic. Stores were doing about $200,000 a year in sales on average with the pots...but they could never have done the $900,000 a year it became without Win's fryer. He (Shelton) helped set the stage for that with true engineering thinking. Although a number of franchisees bought the Collectramatic, which had the support of Colonel Sanders from 1970 onwards, John Y. Brown Jr. had given tacit approval to franchisees to exclusively use the older L S Hartzog fryer, saying "Though those old pots were damn dangerous, at least we knew they worked! I was mostly afraid these new fryers would break down in the middle of business." Brown warned franchisees that they were in violation of their contract if they used the Collectramatic. Brown held his ground on the issue until he learned that his father, John Y. Brown Sr., who owned multiple KFC franchises, was successfully using the Collectramatic in every franchise he owned. The issue was eventually resolved after Heublein purchased KFC, acquired Hartzog and nullified the contract. The Collectramatic has been an approved pressure fryer for KFC from 1972 onwards. From 2013 onwards, KFC has been transitioning from using Collectramatic cookers to pressure fryers produced by Henny Penny, which supplies KFC with various equipment. The 'Velocity' series of pressure fryers includes increased load capacity, automatic oil filtration and increased oil longevity.
(Full) agonists are able to activate the receptor and result in a strong biological response. The natural endogenous ligand with the greatest efficacy for a given receptor is by definition a full agonist (100% efficacy). Partial agonists do not activate receptors with maximal efficacy, even with maximal binding, causing partial responses compared to those of full agonists (efficacy between 0 and 100%). Antagonists bind to receptors but do not activate them. This results in a receptor blockade, inhibiting the binding of agonists and inverse agonists. Receptor antagonists can be competitive (or reversible), and compete with the agonist for the receptor, or they can be irreversible antagonists that form covalent bonds (or extremely high affinity non-covalent bonds) with the receptor and completely block it. The proton pump inhibitor omeprazole is an example of an irreversible antagonist. The effects of irreversible antagonism can only be reversed by synthesis of new receptors. Inverse agonists reduce the activity of receptors by inhibiting their constitutive activity (negative efficacy). Allosteric modulators: They do not bind to the agonist-binding site of the receptor but instead on specific allosteric binding sites, through which they modify the effect of the agonist. For example, benzodiazepines (BZDs) bind to the BZD site on the GABAA receptor and potentiate the effect of endogenous GABA. Note that the idea of receptor agonism and antagonism only refers to the interaction between receptors and ligands and not to their biological effects.
Sources: en.wikipedia.org
==== Multiple products ==== In all of the above examples, the initial nuclide decays into just one product. Consider the case of one initial nuclide that can decay into either of two products, that is A → B and A → C in parallel. For example, in a sample of potassium-40, 89.3% of the nuclei decay to calcium-40 and 10.7% to argon-40. We have for all time t:
Ethylene oxide is one of the most commonly used sterilization methods in the healthcare industry because of its non-damaging effects on delicate instruments and devices that require sterilization, and for its wide range of material compatibility. It is used for instruments that cannot tolerate heat, moisture, or abrasive chemicals, such as electronics, optical equipment, paper, rubber, and plastics. It is the most common chemical sterilization method, used for approximately 70% of total sterilizations, and for over 50% of all disposable medical devices. Ethylene oxide treatment was developed in the 1940s as a sterilant by the US military, and its use as a medical sterilant dates to the late 1950s, when the McDonald process was patented for medical devices. The Anprolene system was patented in the 1960s by Andersen Products, and it remains the most commonly used system in several niche markets, notably the veterinary market and some international markets. It relies on the use of a flexible sterilization chamber and an EtO cartridge for small volume sterilization, and where environmental and/or portability considerations dictate the use of a low dose. It is therefore referred to as the "flexible chamber sterilization" method, or the "gas diffusion sterilization" method. In the United States, the operation of EtO sterilization is overseen by the EPA through the National Emissions Standards for Hazardous Air Pollutants (NESHAP).
=== Bacterial toxins === Bacterial ADP-ribosylating exotoxins (bAREs) covalently transfer an ADP-ribose moiety of NAD+ to target proteins of infected eukaryotes, to yield nicotinamide and a free hydrogen ion. bAREs are produced as enzyme precursors, consisting of a "A" and "B" domains: the "A" domain is responsible for ADP-ribosylation activity; and, the "B" domain for translocation of the enzyme across the membrane of the cell. These domains can exist in concert in three forms: first, as single polypeptide chains with A and B domains covalently linked; second, in multi-protein complexes with A and B domains bound by non-covalent interactions; and, third, in multi-protein complexes with A and B domains not directly interacting, prior to processing.
Thus for a 2 m (6.6 ft) radius glass tube in lab conditions given above, the water would rise an unnoticeable 0.007 mm (0.00028 in). However, for a 2 cm (0.79 in) radius tube, the water would rise 0.7 mm (0.028 in), and for a 0.2 mm (0.0079 in) radius tube, the water would rise 70 mm (2.8 in).
== Distribution and habitat == The giant gourami is native to rivers, streams, marshes, swamps and lakes in Southeast Asia, from the lower Mekong of Cambodia and Vietnam, and Chao Phraya and Mae Klong of Thailand, as well as river basins in the Malay Peninsula, Sarawak of Malaysia, and Java, to Sumatra and Western Kalimantan of Indonesia. However, the exact limits of the natural range are often labelled with uncertainty due to confusion with the other Osphronemus species (which only were scientifically described in 1992 and 1994) and the widespread release of giant gouramis outside their native range. For example, both the giant gourami and elephant ear gourami have been reported from the middle Mekong, and both the giant gourami and O. septemfasciatus have been reported from Borneo in the Kapuas River and river basins in Sarawak. However, middle Mekong records of the giant gourami are likely misidentifications of elephant ear gouramis (the only place in the Mekong basin where the giant gourami likely occurs naturally are in the southernmost part, like tributaries originating in the northern Cardamom Mountains). The presence of giant gouramis in Borneo is possibly the result of introductions. The final species in the genus, the giant red tail gourami, is restricted to Sabah where the others do not occur. This suggests that the different Osphronemus species originally had allo- or parapatric distributions. Whether deliberate or by accident, giant gouramis have been introduced widely as food fish.
Sources: en.wikipedia.org
It usually refers to the relative area of the main peak in a chromatographic separation, such as RP-HPLC. It estimates the proportion of UV-absorbing material in that peak, not the absolute mass fraction of the target peptide. Different methods can give different percentages.
HPLC separates and quantifies components, while mass spectrometry identifies molecular masses. Together they can show whether a main peak has the expected mass and whether other peaks correspond to related peptide variants. This combination is more informative than either method alone.
Higher purity reduces the proportion of detectable related impurities, which can matter for research reproducibility. However, purity value alone does not establish identity, biological activity, or safety. The appropriate purity depends on the intended use and the sensitivity of the assay.
Lyophilized peptides are typically stored at -20 °C or lower, protected from moisture and light. Solutions are often stored at -80 °C and divided into single-use aliquots. Repeated freeze-thaw cycles should be avoided.